NCT01878708View on ClinicalTrials.gov

A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

EARLY_PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
T-Cell LymphomaRelapsed T-Cell LymphomaRefractory T-Cell Lymphoma
Interventions
DRUG

PEG-L-asparaginase

DRUG

Dexamethasone acetate

-dexamethasone 40mg daily for 4 days with every cycle.

Trial Locations (2)

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Leadiant Biosciences, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT01878708 - A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma | Biotech Hunter | Biotech Hunter